- Home
- WWR vs CMMB Comparison
WWR vs CMMB Comparison
Compare WWR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | CMMB |
|---|---|---|
| Founded | 1977 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 19.9M |
| IPO Year | 2006 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WWR | CMMB |
|---|---|---|
| Price | $0.55 | $2.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.92 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 936.6K | 113.5K |
| Earning Date | 05-13-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $64.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $1.35 |
| 52 Week High | $3.75 | $3.55 |
Technical Indicators
Market Signals| Indicator | WWR | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 55.25 |
| Support Level | $0.54 | $1.49 |
| Resistance Level | $0.57 | $2.88 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 1.50 | 22.40 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.